Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Opendoor Technologies Inc (OPEN) vs 10X Genomics Inc (TXG) Price & Performance

Opendoor Technologies IncTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Opendoor Technologies Inc vs 10X Genomics Inc — how do they compare? Opendoor Technologies Inc trades at $3.01 (market cap $2.96B), while 10X Genomics Inc trades at $67.8 (market cap $8.55B). The key difference: 10X Genomics Inc is far larger — about 2.9× Opendoor Technologies Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Opendoor Technologies Inc nearer its low. Which is the better fit depends on your goals.

OPENTXG
Market Cap
$2.96B$8.55B
Sector
Real EstateHealth
52-Week High
$10.52$67.29
52-Week Low
$3.00$11.34
Enterprise Value
$4.03B$8.08B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Opendoor Technologies Inc

Opendoor Technologies (OPEN) trades at $3.07, down 2.54% on the day, near its 52-week low. The stock exhibits a bearish technical trend with negative moving averages, while fundamentals show declining revenue to $4.37 billion in 2025 and a net loss of $1.30 billion. Recent news highlights the launch of Opendoor Home Loans and a $158 million share buyback, but the company faces persistent profitability challenges amid a weak housing market.

The outlook remains cautious with high execution risks and negative margins, though analyst consensus suggests a moderate buy rating with a $3.58 price target. Key risks include housing market sensitivity and capital intensity, but cost-cutting and volume growth offer potential upside if the turnaround gains traction.

10X Genomics Inc

TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.

The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Opendoor Technologies Inc

Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.

Read more on OPEN

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG